918 related articles for article (PubMed ID: 18230901)
41. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity?
Atanasov AG; Odermatt A
Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):125-40. PubMed ID: 17584152
[TBL] [Abstract][Full Text] [Related]
42. Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
Morris DJ; Latif SA; Hardy MP; Brem AS
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):161-8. PubMed ID: 17459698
[TBL] [Abstract][Full Text] [Related]
43. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
44. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
45. Tissue-specific dysregulation of cortisol metabolism in human obesity.
Rask E; Olsson T; Söderberg S; Andrew R; Livingstone DE; Johnson O; Walker BR
J Clin Endocrinol Metab; 2001 Mar; 86(3):1418-21. PubMed ID: 11238541
[TBL] [Abstract][Full Text] [Related]
46. Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Wiegand S; Richardt A; Remer T; Wudy SA; Tomlinson JW; Hughes B; Grüters A; Stewart PM; Strasburger CJ; Quinkler M
Eur J Endocrinol; 2007 Sep; 157(3):319-24. PubMed ID: 17766714
[TBL] [Abstract][Full Text] [Related]
47. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
Saiah E
Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
[TBL] [Abstract][Full Text] [Related]
48. Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11β-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue.
Tagawa N; Minamitani E; Yamaguchi Y; Kobayashi Y
Steroids; 2011 Dec; 76(14):1546-53. PubMed ID: 21945397
[TBL] [Abstract][Full Text] [Related]
49. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
50. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
[TBL] [Abstract][Full Text] [Related]
51. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.
Morgan SA; Tomlinson JW
Expert Opin Investig Drugs; 2010 Sep; 19(9):1067-76. PubMed ID: 20707593
[TBL] [Abstract][Full Text] [Related]
52. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
53. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity.
Hughes KA; Webster SP; Walker BR
Expert Opin Investig Drugs; 2008 Apr; 17(4):481-96. PubMed ID: 18363514
[TBL] [Abstract][Full Text] [Related]
54. Transgenic overexpression of hexose-6-phosphate dehydrogenase in adipose tissue causes local glucocorticoid amplification and lipolysis in male mice.
Wang Y; Liu L; Du H; Nagaoka Y; Fan W; Lutfy K; Friedman TC; Jiang M; Liu Y
Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E543-51. PubMed ID: 24381005
[TBL] [Abstract][Full Text] [Related]
55. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Oppermann U
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
[TBL] [Abstract][Full Text] [Related]
56. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
57. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
[TBL] [Abstract][Full Text] [Related]
58. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
59. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Stulnig TM; Waldhäusl W
Diabetologia; 2004 Jan; 47(1):1-11. PubMed ID: 14652720
[TBL] [Abstract][Full Text] [Related]
60. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
